🦟🗺️Half of the human population lives in areas at risk of Dengue...and it is growing under the pressure of global warming🔥🌏🔥
If you have had Dengue before (a viral infection vectored by mosquitoes), you will be painfully aware of how even mild cases can affect your health and productivity for months 🤒🛌⏳
Getting it a second time carries the risk of antibody-dependent enhancement which may even be fatal.
That is why it is important to make cell-mediated vaccines that don't produce antibodies💉
It was extremely interesting to write the protocol for this phase I clinical trial called NaNo-Dengue: a first-in-human test of the gold-nanoparticle-based peptide PepGNP produced by Emergex Vaccines
The trial was expertly executed under the meticulous care of Alix Miauton and the Unisanté team Regine Audran Juliette Besson, Hélène Maby-El Hajjami, MaximeKarlen Loane Warpelin-Decrausaz, Loredana Sene, Sylvain Schaufelberger, Vincent Faivre, Mohamed Faouzi François Spertini, Blaise Genton
Super proud to be part of this work and have the opportunity to work with this great team! 💗
Watch this space for NaNo-COVID coming soon!
🫶Thank you to our courageous participants 🫶
Image: Gold Nano-particle vaccine for Dengue, by DALL-E 3